Evidence map›Paper›PMID 26418670›Full record

Trial reportScandinavian journal of gastroenterology2016

Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience.

Jesper Waldenström, Martti Färkkilä, Karolina Rembeck, Gunnar Norkrans, Nina Langeland, Kristine Mørch, Court Pedersen, Mads Rauning Buhl, Urpo Nieminen, Hannu Nuutinen and 8 more

Open access · hybridAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scandinavian journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 13 institutions in 4 countries.

Jesper Waldenströma Department of Infectious Medicine/Virology , Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg , Sweden ;
Martti Färkkiläb Clinic of Gastroenterology, Helsinki University Hospital, University of Helsinki , Helsinki , Finland ;
Karolina Rembecka Department of Infectious Medicine/Virology , Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg , Sweden ;
Gunnar Norkransa Department of Infectious Medicine/Virology , Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg , Sweden ;
Nina Langelandc Department of Clinical Science , University of Bergen , Bergen , Norway ;
Kristine Mørchd Department of Medicine , Haukeland University Hospital , Bergen , Norway ;
Court Pedersene Department of Infectious Diseases , University of Southern Denmark , Odense , Denmark ;
Mads Rauning Buhlf Department of Infectious Diseases , Aarhus University , Aarhus , Denmark ;
Urpo Nieminenb Clinic of Gastroenterology, Helsinki University Hospital, University of Helsinki , Helsinki , Finland ;
Hannu Nuutinenb Clinic of Gastroenterology, Helsinki University Hospital, University of Helsinki , Helsinki , Finland ;
Åsa Alsiög Infektion, Skaraborgs Sjukhus Skövde , Skövde , Sweden ;
Lars Holmströmh Infektionskliniken, Hallands sjukhus , Halmstad , Sweden ;
Rolf Jungneliusi Infektionskliniken, Södra Älvsborgs Sjukhus , Borås , Sweden ;
Katarina Lundj Infektionskliniken, NÄL , Trollhättan , Sweden ;
Anders Rubenssonk Infektionskliniken, Centralsjukhuset , Karlstad , Sweden.
Erik Torelll Infektionskliniken, Gävle Sjukhus , Gävle , Sweden.
Johan Westina Department of Infectious Medicine/Virology , Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg , Sweden ;
Martin Lagginga Department of Infectious Medicine/Virology , Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg , Sweden ;
University of Gothenburg · SEUniversity of Helsinki · FIAarhus University · DKGävle Hospital · SEHallands sjukhus Halmstad · SEHaukeland University Hospital · NOHelsinki University Hospital · FIKarlstad Central Hospital · SENorra Älvsborgs Länssjukhus · SESkaraborg Hospital · SESödra Älvsborg Hospital · SEUniversity of Bergen · NOUniversity of Southern Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveInterferon-free therapy for hepatitis C virus (HCV) infection is costly, and therefore patients with advanced fibrosis are prioritized. Although coupled with considerable side effects, a large proportion of genotype 2/3 infected patients achieve a sustained virological response (SVR) following interferon-based therapy. The present study evaluates experimental clinical trial and verifying real-life data with the aim of identifying patients with a high likelihood of favorable outcome following short interferon-based treatment. MATERIAL AND

methodsThe impact of established response predictors, e.g. age, ITPA and IL28B genetic variants, IP-10, liver histopathology and early viral kinetics on outcome was evaluated among HCV genotype 2/3 infected patients enrolled in the NORDynamIC trial. Similarly outcome was evaluated among Finnish and Swedish real-life genotype 2/3 infected patients treated for 12-16 weeks in accordance with national guidelines.

resultsIn the NORDynamIC trial, age < 40 years or achieving HCV RNA < 1000 IU/mL day 7 were highly predictive of favorable outcome following 12 weeks therapy. Among 255 Finnish real-life patients below the age of 40 years treated for 12 weeks with interferon and ribavirin, 87% of HCV genotype 2 and 79% of genotype 3 infected patients achieved SVR, and among 117 Swedish real-life patients treated for 12-16 weeks, 97% of HCV genotype 2 and 94% of genotype 3 infected achieved SVR.

conclusionsShort interferon-based therapy offers a high likelihood of achieving SVR for selected HCV genotype 2/3 infected patients, and is an acceptable option given that a thorough discussion of the side effects is provided prior to initiation.

Indexed as

AdultAge FactorsAntiviral AgentsChemokine CXCL10Drug Therapy, CombinationGenotypeHepacivirusHepatitis C, ChronicHumansInosine TriphosphataseInterferon-alphaInterferon LambdaInterferonsInterleukinsMiddle AgedPolyethylene GlycolsAntiviral AgentsChemokine CXCL10CXCL10 protein, humanInosine TriphosphataseInterferon-alphaInterferon Lambdainterferon-lambda, humanInterferonsInterleukinsITPA protein, humanpeginterferon alfa-2aPolyethylene GlycolsPyrophosphatasesRecombinant ProteinsRibavirinRNA, Viralgenotype 2genotype 3hepatitis C virusinosine triphosphate pyrophosphataseinterferonITPAribavirin

Identifiers

PMID26418670
PMCPMC4732462
OpenAlexW1776457637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.